Ad
related to: dna research impact factor bioxbio cancer
Search results
Results From The WOW.Com Content Network
DNA Research is an international, ... In 2014, the journal's impact factor was 5.477, ranking 22nd out of 167 in the category 'Genetics & Heredity'. The journal is ...
Nucleic Acids Research is an open-access peer-reviewed scientific journal published since 1974 by the Oxford University Press. The journal covers research on nucleic acids, such as DNA and RNA, and related work. According to the Journal Citation Reports, the journal's 2021 impact factor is 19.160. [1]
Current Cancer Drug Targets is a peer-reviewed medical journal published by Bentham Science Publishers. The editor-in-chief is Ruiwen Zhang ( UH Drug Discovery Institute). The journal covers research on contemporary molecular drug targets involved in cancer , including medicinal chemistry , pharmacology , molecular biology , genomics , and ...
As of 2014, Biochimica et Biophysica Acta encompasses ten specialised sections with a total of 100 annual issues in ten volumes. Over 16,000 pages were published in 2011. The journal sections are published separately, with one annual volume per section (two for Reviews on Cancer), but form part of the volume numbering for Biochimica et Biophysica Acta.
Cancer Immunology Research is a monthly peer-reviewed medical journal published by the American Association for Cancer Research. It covers research and clinical trials related to the study of cancer immunology. The editors-in-chief are Robert D. Schreiber and Philip Greenberg. [1] The journal was established in 2013. [1]
Cancer Cell is internationally regarded as one of the top cancer research and oncology journals. According to the Journal Citation Reports, the 2022 impact factor of the journal is 50.3. It is part of the Cell Press portfolio, which is owned by Elsevier. Issues are published monthly in print and online versions.
Molecular Cancer is a peer-reviewed open-access scientific journal covering all aspects of cancer research. The journal is published by BioMed Central and was established in 2002. The first editor-in-chief was Chi V. Dang, who is also the scientific director of the Ludwig Institute for Cancer Research . [ 1 ]
The journal publishes both full-length and mini-reviews, original research, meta-analysis, and results from clinical studies. In addition, the journal has published manuscripts focused on ethical and regulatory considerations of gene and cell therapy. As well as important regulatory, manufacturing, and logistical aspects of gene therapy research.
Ad
related to: dna research impact factor bioxbio cancer